Sign up Australia
Proactive Investors - Run By Investors For Investors

Medlab Clinical to begin trials of cannabis based medicines

Expected to meet a global need for better cancer pain management.
Medlab Clinical to begin trials of cannabis based medicines
Both clinical trials have received ethics committee approvals

Medlab Clinical (ASX:MDC) has received approvals to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial.

NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage cancer patients with intractable pain.

The drug is expected to meet a global need for better pain management, with research having shown cancer pain was an increasingly widespread condition.

Recent statistics regarding cancer pain indicate it is prevalent in 64% of patients with metastatic or advanced-stage disease and that for one in two patients with cancer, it is undertreated.

With the recent U.S. crackdown on opioid abuse, there is a significant need for better, efficacious treatment.

NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures.

The drug is intended to be made available to general practitioners so it would give many Australians access to a drug which governments around the country have been keen to see introduced.

Both clinical trials have received Human Research Ethics Committee (HREC) approvals and are expected to commence shortly.

Recent research on the legal cannabis industry in North America showed consumers spent US$6.9 billion on legal cannabis products in 2016, up 34% from 2015.





Register here to be notified of future MDC Company articles
View full MDC profile View Profile

Medlab Clinical Timeline

Related Articles

diagram of the human microbiome
September 13 2017
OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use